While I personally don't believe Ampligen will receive FDA approval and I'm not a fan of the company, I do see an excellent trading opportunity as we get closer to the FDA advisory panel. Make note that Hemispherx's share price has already increased over 100% since late July, which could lessen the run-up trade opportunity.
Hemispherx can raise cash through an existing $75 million "At-The-Market" equity credit facility and just received shareholder approval to use up to 75 million shares for fund-raising purposes. The expectation that a company is planning to dilute and raise cash can tamp down the run-up trade.
And remember, Hemispherx is a trade, not an investment. Never fall in love with a small-cap biotech stock.
Messier has no positon in Hemispherx.